APLLTD Q2 FY27 Guidance vs Delivery (APLLTD Management Mirror)

Did APLLTD's management deliver what it guided? Guidance vs actual performance and tone changes across recent earnings calls, as of the Q2 FY27 (Sep-2026 Qtr) concall.

Alembic Pharmaceuticals Ltd (APLLTD) Q2FY27 Management Mirror - Sep-2026 Qtr

FY27 Consolidated Revenue Growth Upgraded to 20%-25% From Mid-Teens Guided in Jun'26 Qtr

In Sep'26 Qtr, consolidated revenue was reported at INR 2,603 crores in the Quarterly Financial Results, growing 36.3% YoY. Driven by this strong performance, management upgraded the full-year FY27 consolidated revenue growth guidance to 20% to 25% YoY, raised from the mid-teens range guided in the Jun'26 Qtr concall, which itself was an upward revision from the initial low double-digit target set in Mar'26 Qtr. Looking ahead, this upgraded growth expectation incorporates the anticipated normalization of exclusivity-led sales in the second half of FY27.

4 more themes on the ELITE plan.